Physician profile
Faye Cohen
NPI 1306808548
$7,181.61
in general payments reported to CMS, 2019-2025
35 companies · $1,331 in 2025
The $1,331 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,286 · 2020: $271 · 2021: $141 · 2022: $1,095 · 2023: $1,643 · 2024: $1,415 · 2025: $1,331.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,314 · Education: $74.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,313.76 |
| Education | $74.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,316.82 | 2019-2025 | |
| Abbvie INC. | $980.45 | 2019-2025 | Rinvoq, Skyrizi |
| Amgen INC. | $913.81 | 2019-2025 | Tavneos, Otezla, Enbrel |
| Janssen Biotech, INC. | $798.35 | 2019-2025 | Tremfya |
| Ucb, INC. | $417.51 | 2019-2025 | Bimzelx, Cimzia |
| Novartis Pharmaceuticals Corporation | $417.16 | 2019-2025 | |
| Glaxosmithkline, LLC. | $377.57 | 2022-2025 | Benlysta, Nucala, Shingrix |
| Lilly USA, LLC | $274.22 | 2019-2025 | Mounjaro, Taltz, Zepbound |
| Novo Nordisk INC | $240.85 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Janssen Pharmaceuticals, INC | $178.20 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $116.95 | 2019-2025 | Xifaxan |
| Astrazeneca Pharmaceuticals LP | $110.29 | 2023-2025 | Saphnelo, Breztri |
| Fresenius Kabi USA, LLC | $93.79 | 2023-2024 | Idacio |
| Ani Pharmaceuticals, INC. | $90.97 | 2025 | Purified Cortrophin Gel |
| Genentech USA, INC. | $88.16 | 2019-2024 | Actemra |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $79.65 | 2022 | |
| Organon LLC | $71.91 | 2024-2025 | Hadlima |
| Sumitomo Pharma America, INC. | $66.44 | 2024-2025 | Gemtesa |
| Exact Sciences Corporation | $65.35 | 2024-2025 | Cologuard Collection Kit |
| E.R. Squibb & Sons, L.L.C. | $57.92 | 2019-2024 | Orencia |
| Sunovion Pharmaceuticals INC. | $53.01 | 2022 | |
| Aurinia Pharma U.S., INC. | $50.67 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $42.82 | 2024-2025 | Zoryve |
| Sanofi Pasteur INC. | $36.10 | 2019-2021 | |
| Amarin Pharma, INC. | $35.96 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.75 | 2023 | Cyltezo |
| Sandoz INC. | $30.54 | 2024 | Hyrimoz |
| Horizon Therapeutics Plc | $26.00 | 2019-2023 | Krystexxa |
| Pacira Therapeutics, INC. | $23.70 | 2019 | |
| Astellas Pharma US INC | $20.63 | 2020 | |
| Octapharma USA, INC. | $16.92 | 2024 | Octagam Immune Globulin (Human) |
| Idorsia Pharmaceuticals US INC | $15.89 | 2022 | |
| Acerus Pharmaceuticals Corporation | $14.53 | 2022 | |
| Shire North American Group INC | $14.28 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.44 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Faye Cohen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.